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Abstract
Background: Women with endometriosis often experience gastrointestinal symptoms. Gonadotropin-releasing
hormone (GnRH) analogs are used to treat endometriosis; however, some patients develop gastrointestinal
dysmotility following this treatment. The aims of the present study were to investigate gastrointestinal symptoms
among patients with endometriosis and to examine whether symptoms were associated with menstruation,
localization of endometriosis lesions, or treatment with either opioids or GnRH analogs, and if hormonal treatment
affected the symptoms.
Methods: All patients with diagnosed endometriosis at the Department of Gynecology were invited to participate
in the study. Gastrointestinal symptoms were registered using the Visual Analogue Scale for Irritable Bowel
Syndrome (VAS-IBS); socioeconomic and medical histories were compiled using a clinical data survey. Data were
compared to a control group from the general population.
Results: A total of 109 patients and 65 controls were investigated. Compared to controls, patients with endometriosis
experienced significantly aggravated abdominal pain (P = 0.001), constipation (P = 0.009), bloating and flatulence
(P = 0.000), defecation urgency (P = 0.010), and sensation of incomplete evacuation (P = 0.050), with impaired
psychological well-being (P = 0.005) and greater intestinal symptom influence on their daily lives (P = 0.001). The
symptoms were not associated with menstruation or localization of endometriosis lesions, except increased nausea
and vomiting (P = 0.010) in patients with bowel-associated lesions. Half of the patients were able to differentiate
between abdominal pain from endometriosis and from the gastrointestinal tract. Patients using opioids experienced
more severe symptoms than patients not using opioids, and patients with current or previous use of GnRH analogs
had more severe abdominal pain than the other patients (P = 0.024). Initiation of either combined oral contraceptives
or progesterone for endometriosis had no effect on gastrointestinal symptoms when the patients were followed
prospectively.
Conclusions: The majority of endometriosis patients experience more severe gastrointestinal symptoms than controls.
A poor association between symptoms and lesion localization was found, indicating existing comorbidity between
endometriosis and irritable bowel syndrome (IBS). Treatment with opioids or GnRH analogs is associated with
aggravated gastrointestinal symptoms.
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Background
Endometriosis is a benign, gynecological disease associated
with the primary symptoms of chronic pelvic pain, deep
dyspareunia, and dysmenorrhea [1]. The prevalence of
endometriosis differs in the literature, but is estimated to
affect approximately 7–10 % of women [2]. Clinically,
women with endometriosis commonly experience
gastrointestinal symptoms, and one study has shown
that gastrointestinal symptoms are almost as common
as gynecological symptoms in these patients [3].
Gastrointestinal symptoms among patients with endo-
metriosis described in the literature include abdominal
pain, bloating, nausea, constipation, vomiting, painful bowel
movements, and diarrhea [3–5]. However, reported symp-
toms differ between studies. Aggravated symptoms during
menstruation have been reported [4, 6, 7] such as cyclic-
related bloating and constipation [4]. Fauconnier et al. [7]
concluded that symptoms including diarrhea, constipa-
tion, and colic rectal pain were more frequent among
patients with endometriosis lesions within or close to
the bowel. In contrast, Maroun et al. [3] reported gastro-
intestinal symptoms to be primarily independent of
localization of endometriosis lesions in relation to the
bowel. Different explanations concerning the occurrence of
these symptoms include: endometriosis lesions cause in-
flammatory activity and local prostaglandin release, which
can alter bowel function [8]; endometriosis lesions within
the bowel cause symptoms due to mechanical obstruction
or cyclic micro-hemorrhages [9]; or there is an existing co-
morbidity between endometriosis and irritable bowel
syndrome (IBS) [8].
Gonadotropin-releasing hormone (GnRH) is a hypothal-
amic hormone [10], which has also been shown to be
present in neurons in the human enteric nervous system
(ENS) [11]. Recent studies have suggested a link between
GnRH and gastrointestinal function [12, 13], and some
patients develop severe dysmotility in the form of chronic
intestinal pseudo-obstruction (CIPO) or enteric dysmotility
(ED) after treatment with GnRH analogs in relation to in
vitro fertilization (IVF) or endometriosis [14]. Full-
thickness biopsies of the bowel wall have shown enteric
neurodegeneration with almost total absence of GnRH-
containing neurons [11, 14, 15]. Hammar et al. [13] investi-
gated 124 patients before and after treatment with GnRH
analogs and concluded that there was a significant exacer-
bation of gastrointestinal symptoms after treatment, and
abdominal pain was still exacerbated at 5-year follow-up.
The aim of the present study was to investigate the se-
verity of gastrointestinal symptoms among patients with
endometriosis compared to a control group from the
general population. Furthermore, an association between
symptoms and menstruation, localization of endometriosis
lesions, and treatment with opioids or GnRH analogs was
investigated. The final aim was to investigate women
initiating hormonal treatment to examine whether this
treatment had an impact on gastrointestinal symptoms over
time.
Methods
This study was approved by the Ethics Review Board of
Lund University, Dnr 2012/564, and performed in ac-
cordance with the declaration of Helsinki. All subjects
gave their written, informed consent before inclusion in
the study.
Patients
Patients who had sought treatment for endometriosis in
the past 5 years were recruited from the Department of
Gynecology at Skåne University Hospital in Malmö.
The patients were identified with the International
Statistical Classification of Diseases and Related Health
Problems, ICD-10, N80.1, 80.4, 80.5, 80.8, and 80.9
from Skåne University Hospital medical records. The
clinic’s catchment area is the southernmost districts of
Sweden. The recruitment was conducted continuously
from March 2013 through July 2014. Inclusion criteria
were a diagnosis of endometriosis made by laparos-
copy, ultrasonography, or a definite clinical diagnosis
made by a gynecologist. The included patients were also
required to comprehend the Swedish or English language.
Exclusion criteria were an uncertain diagnosis of endo-
metriosis, patients living too far from the geographical
area of Skåne University Hospital, multi-morbidity,
current pregnancy, or a diagnosis of cancer, inflamma-
tory bowel disease, multiple sclerosis, psychiatric dis-
ease, or rheumatoid arthritis.
Controls
Data regarding control subjects was obtained from a
previous study conducted by Hammar et al. [13]. In this
study, control subjects were randomly acquired from the
Swedish Population Registry, and 248 subjects were con-
tacted. In total, after one reminder, 29 questionnaires
were returned. Because of the low response rate, further
controls were recruited amongst female hospital staff. In
total, 65 women representing the general population,
with a mean age of 40 ± 9 years, were recruited and
completed the Visual Analogue Scale for Irritable Bowel
Syndrome (VAS-IBS).
Study design
The patients were contacted via mail, and within a week,
they were also contacted via telephone. After agreement
to participate in the study, an appointment for an inter-
view and a blood draw was done 1–4 weeks after inclu-
sion in the study. The questionnaire, Visual Analogue
Scale for Irritable Bowel Syndrome (VAS-IBS), and a
clinical data survey were sent via mail, with instructions
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to complete these questionnaires at a maximum of 1
week before the appointment. At the hospital visit, all
patients were interviewed regarding previous treatment
for endometriosis and their position in the menstrual
cycle at the time of completing the VAS-IBS. The pa-
tients who were included at the first contact with the
Department of Gynecology also completed the VAS-IBS
questionnaire and the clinical data survey, were inter-
viewed and had blood samples drawn at 3 and 6 months
after their first visit.
A review of the patients’ medical journals was con-
ducted to investigate the localization of endometriosis
lesions, current hormonal treatment, and whether they
had undergone diagnostic or operative laparoscopy. A
lesion was confirmed when it was seen macroscopically
during laparoscopy, visualized by ultrasonography, or in
a few cases by palpation conducted by a gynecologist.
Questionnaires
Clinical data survey
The clinical data survey addresses socioeconomic fac-
tors, physical exercise, nicotine- and alcohol habits,
current diseases, and medication, as well as questions
about gastrointestinal symptoms such as onset and trig-
gers, whether the subject can differentiate between the
abdominal pain from endometriosis and the gastrointes-
tinal tract, and whether pharmacological treatment was
used because of the complaints.
Three questions were added after the study was initi-
ated: which year endometriosis-associated symptoms
began; which year gastrointestinal symptoms began; and
whether the patient could differentiate symptoms from
endometriosis and symptoms from the gastrointestinal
tract. Therefore, an additional survey with these ques-
tions was sent by mail to the 21 first participants already
included in the study.
Visual Analogue Scale for Irritable Bowel Syndrome
The VAS-IBS was used to investigate gastrointestinal com-
plaints in the study groups. It is a validated questionnaire
for estimation of the most common gastrointestinal com-
plaints in patients with non-organic, functional bowel dis-
ease [16]. This scale has also been validated for estimation
of symptoms over time [17]. The seven items measured in
the VAS-IBS address the symptoms abdominal pain, diar-
rhea, constipation, bloating and flatulence, nausea and
vomiting, psychological well-being, and intestinal symp-
toms’ influence on daily life. These items were measured
on a scale from 0 to 100, where 0 represents severe prob-
lems and 100 represents a complete lack of problems. An
additional two questions, if the subject experienced
defecation urgency and had a sensation of incomplete
evacuation, were answered with yes or no.
Statistical methods
The data was analyzed using the statistical software
package SPSS for Windows (release 22.0; IBM). Because
the controls were slightly older than the endometriosis
patients, variables were age-standardized using a linear
regression model into which age was added as a covari-
ate and the variables were then expressed as z-scores.
When comparing VAS scores between groups, the age-
standardized values were used. All variables were analyzed
for normal distribution using the Kolomogorov-Smirnov
test. As normality was rejected, except for age, the Mann-
Whitney U-test and the Fisher’s exact test were used to
compare different groups. Student t-test was used to per-
form a failure analysis. To calculate differences within the
group, Friedman’s test and Wilcoxon’s signed rank test were
used. Spearman’s correlation test was used for correlations
between age and symptoms. Values were expressed as
mean ± standard deviation (SD), median [interquartile




A total of 627 patients with suspected endometriosis
were identified. Of these, 320 were excluded because
they either did not fulfill the inclusion criteria or they
fulfilled the exclusion criteria. The most common reason
for exclusion was uncertainty about the diagnosis. Then,
307 patients remained who fulfilled the inclusion cri-
teria. Of these, 198 patients were excluded since 144
were not willing to participate, 49 had moved from the
region, and 4 denied the diagnosis when contacted.
Thus, 109 could finally be included in the study. Eighteen
of these patients were followed prospectively regarding
their gastrointestinal symptoms, and 14 of these initiated a
new hormonal treatment for endometriosis during the
study period.
The mean age of the 109 included patients was 37 ±
7 years. The median duration of endometriosis was 8.5
(4.0–16.0) years. Patients who were unwilling to participate
in the study were younger (35 ± 6 years) than those who
participated (P = 0.014). Almost two-thirds of the patients
had a degree from a university or a college. The vast major-
ity had never smoked and consumed less than one standard
glass of alcohol a week (Table 1). Aside from endometriosis
the majority of patients were healthy (n = 57), and the most
common diseases reported were allergies or bronchial
asthma (n = 18) followed by migraine (n = 7) and irritable
bowel syndrome (IBS) (n = 6).
Almost all patients had received hormonal treatment
for endometriosis, most commonly combined oral con-
traceptives (Table 2). Of the 109 patients, 87 had
laparoscopically-verified endometriosis, 21 had received
their diagnosis by ultrasonography, and only one was
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diagnosed clinically. The most common localization of
endometriosis lesions was in the ovaries (n = 83),
followed by the peritoneum (n = 21), the bowel (n = 18),
and the Pouch of Douglas (n = 16).
Patients’ gastrointestinal complaints
Of the patients, 85 % reported gastrointestinal complaints
during the past year. The onset of symptoms had been
gradual for a majority. The median duration of gastro-
intestinal symptoms was 5 months shorter than the me-
dian duration of endometriosis. One-third of the patients’
complaints had been diagnosed as IBS or endometriosis,
but one out of five reported never having received any
diagnosis for the symptoms. However, almost half of the
patients reported having the ability to differentiate be-
tween pain symptoms from endometriosis and from the
gastrointestinal tract. A variety of different triggers for the
symptoms were described (Table 3). Nearly half of the pa-
tients had received pharmacological treatment for their
Table 1 Patient characteristics
Patients with
endometriosis n = 109
Age (years) 36.78 ± 7.39
BMI (kg/m2), missing value = 4 24.00 (22.00–26.00)
Marital status (n, %), missing value = 1
Living alone 36, 33.0
Married or living with a partner 70, 64.2
Living with parents 2, 1.8
Education (n, %)
Not completed elementary school 1, 0.9
Completed elementary school 2, 1.8
Completed secondary school 20, 18.3
More than a year of further education
after secondary school
24, 22.0
Degree from university or college 62, 56.9
Occupation (n, %), missing value = 1
Work full time 62, 56.9
Work 99–51 % 22, 20.2
Work 1–50 % 8, 7.3




Smoking habits (n, %)
Smoke regularly 8, 7.3
Smoke occasionally 10, 9.2
Do not smoke, but have been a smoker 21, 19.3
Have never smoked 70, 64.2
Snuff habits (n, %)
Snuff regularly 6, 5.5
Do not snuff but have been a regular snuff
user
3, 2.8
Have never used snuff 100, 91.7
Alcohol use (n, %)
Less than one standard glass a week 68, 62.4
1–4 standard glasses a week 31, 28.4
5–9 standard glasses a week 10, 9.2
Physical exercise (n, %)
No time 18, 16.5
Less than 30 minutes a week 16, 14.7
30–90 minutes a week 37, 33.9
More than 90 minutes a week 38, 34.9
BMI = body mass index; n, % = number and percentage of patients. One
standard glass of alcohol contains 12 grams of pure alcohol. Physical exercise
was defined as physical activity that results in shortness of breath. Values are
given as mean ± standard deviation, median [interquartile range (IQR)] and
number, %




Previous or current hormonal treatment (n)
Any type of hormonal treatment 106




Current hormonal treatment (n), missing value = 23
Combined oral contraceptives 27
Progesterone 24
No hormonal treatment 24
GnRH analogs 9
Estrogen 2
Onset of gastrointestinal symptoms
after hormonal treatment (Yes/No/Unknown)
23/27/59
Type of hormonal treatment causing symptoms (n)
After/during IVF 6
After cessation of combined oral
contraceptives
5
After progesterone medication 3
After or during usage of an IUD 2
After GnRH treatment 2
After Pergotime (Klomifen) treatment 1
IVF = in vitro fertilization; GnRH = gonadotropin-releasing hormone;
IUD = intrauterine device; n = number of patients. Patients presented can have
had more than one hormonal treatment and have stated more than one
hormonal treatment as the onset trigger for gastrointestinal symptoms.
Patients assigned to the group “GnRH analogs” are those who reported GnRH
analogs when asked about hormonal treatment and those who reported
having undergone IVF. Values are given as number
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gastrointestinal complaints; slightly less than one out of five
had been treated with opioids, and almost half of the pa-
tients had been treated with other drugs than opioids, for
example nonsteroidal anti-inflammatory drugs (NSAID),
paracetamol, or anti-depressant medication. However, in
many cases, it was not obvious whether the anti-depressant
drugs were given for treatment of abdominal pain or de-
pression (Table 4).
Gastrointestinal symptoms measured by the Visual
Analogue Scale for Irritable Bowel Syndrome
Patients with endometriosis experienced aggravated symp-
toms compared to controls regarding abdominal pain,
constipation, bloating and flatulence, and impaired psy-
chological well-being and greater influence of intestinal
symptoms on daily life. The endometriosis patients also ex-
perienced defecation urgency and a sensation of incomplete
evacuation significantly more often (Table 5). Increasing pa-
tient age correlated with less diarrhea (rs= 0.281, P = 0.03),
less bloating and flatulence (rs= 0.239, P = 0.013), less nau-
sea and vomiting (rs= 0.286, P = 0.003), and better psycho-
logical well-being (rs= 0.295, P = 0.002), whereas age in
controls did not correlate with symptoms (data not shown).
The patients with lesions within the bowel, or in close
proximity to the bowel (the pouch of Douglas, the posterior
wall of the vagina, or the recto-vaginal septum) (n = 34),
scored more severe symptoms regarding nausea and vomit-
ing than the other patients [69.71 (33.75–100.00) vs. 84.36
(75.00–100.00); P = 0.010]. None of the other symptoms
differed depending on localization of the lesions (data not
shown).
The patients currently using opioids scored more se-
vere symptoms than the other patients regarding all
symptoms except sensation of incomplete evacuation
(Table 6). The patients who were not currently using opi-
oids scored more severe symptoms than controls regarding
abdominal pain [66.12 (45.00–100.00) vs. 81.40 (73.00–
98.00); P = 0.013], bloating and flatulence [53.96 (20.00–
90.00) vs. 71.72 (41.75–96.00); P = 0.005], intestinal symp-
toms’ influence on daily life [66.01 (35.00–100.00) vs. 81.28
(75.00–98.00); P = 0.011], and sensation of incomplete
evacuation [45 (47.4 %) vs. 17 (26.2 %); P = 0.016]. The fol-
lowing parameters all showed tendency towards significant
differences between patients not using opioids and controls:
constipation [68.88 (45.00–100.00) vs. 84.47 (83.00–98.00);
P = 0.051], psychological well-being [68.74 (50.00–100.00)
vs. 82.07 (74.00–96.00); P = 0.064], and defecation urgency
[29 (30.5 %) vs. 11 (16.9 %); P = 0.066].
The patients who currently received hormonal treat-
ment for endometriosis (combined oral contraceptives,
progesterone, estrogen, or GnRH analogs) (n = 62) did not
experience more severe gastrointestinal symptoms than
the other patients (n = 24) (data not shown). However,
when comparing patients with current or previous GnRH




Onset of gastrointestinal symptoms (n, %),
missing value = 19
Gradual 70, 64.2
Rapid 20, 18.3
Duration of gastrointestinal complaints (years) 8.00 (4.00–15.50)
The evolution of symptoms over time (n, %),
missing value = 17
Constant complaints 14, 12.8
Intermittent complaints 45, 41.3
Progressively worse 33, 30.3
Gastrointestinal complaints during the last year
(Yes/No)
93/16
Ability to differentiate between pain due to
endometriosis and from the gastrointestinal tract
(Yes/No/Unknown)
53/32/24
Has changed occupation because of complaints
(Yes/No/Unknown)
5/101/3
Relatives with similar complaints (Yes/No/Unknown) 46/47/16
Experience a trigger for the complaints
(Yes/No/Unknown)
35/55/19




Cessation of combined oral contraceptives 4
Endometriosis 3

















IBS = irritable bowel syndrome, n, % = number and percentage of subjects.
Patients presented can have more than one trigger for gastrointestinal
symptoms and more than one diagnosis ascribed to the symptom. Values are
given as median [interquartile range (IQR)] and number, %
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treatment (n = 55) towards the other patients (n = 51),
there was a higher degree of abdominal pain among the
first group [55.35 (25.00–91.25) vs. 69.51 (50.00–100.00);
P = 0.024]. Among those who had no hormonal treatment,
the patients who were currently menstruating (n = 3),
were compared to those who did not menstruate (n = 21),
and no significant differences regarding symptoms be-
tween the groups were found (data not shown).
Prospective follow-up of gastrointestinal symptoms
during treatment
Of the 14 patients initiating a new hormonal treatment
for endometriosis, the only significant effect was im-
proved psychological well-being from 0 to 3 months,
followed by impaired well-being from 3 to 6 months
(Friedman’s test; P = 0.006). When performing subgroup
analyses, the patients who had initiated a new treatment
with combined oral contraceptives (n = 5) did not ex-
perience any significant reduction in any of the symp-
toms over time (data not shown). Subgroup analyses in
patients who had initiated treatment with progesterone
(n = 6) showed a significant effect regarding psycho-
logical well-being, which had improved at the 3-month
follow-up but was impaired at the 6-month follow-up
(Friedman’s test; P = 0.016).
Discussion
Compared to controls, endometriosis patients experi-
ence more abdominal pain, constipation, bloating and
flatulence, influence of intestinal symptoms on daily life,
defecation urgency, sensation of incomplete evacuation,
and decreased psychological well-being. Localization of
endometriosis lesions showed no association with symp-
toms, except lesions within or close to the bowel, which
were associated with more nausea and vomiting. Patients
using opioids had more severe symptoms than patients
not using opioids, and patients treated with GnRH ana-
logs had more abdominal pain than the other patients. A
prospective analysis of patients initiating a new hormo-
nal treatment of endometriosis during the study showed
no impact from treatment of gastrointestinal symptoms
over time. In contrast, prior studies have shown that
progestins relief gastrointestinal symptoms related to the
menstrual cycle, as well as overall diarrhea and intestinal
cramping [18]. However, the latter study could not de-
tect any effect of progestins on overall constipation, ab-
dominal bloating and feeling of incomplete evacuation
[18]. The difference between studies is that the present





Examinations conducted because of gastrointestinal
symptoms (n)
Diagnostic laparoscopy (without surgery) 30








Previous or current pharmacological treatment
because of gastrointestinal complaints
(Yes/No/Unknown)
Opioids 20/88/1
Other analgesic treatment than opioids 21/78/10
Other pharmacological treatment than analgesics 29/70/10
Types of pharmacological treatment other than opioids
for gastrointestinal complaints (n)
NSAIDs 16




Gabapentin or pregabalin 2




Types of current medication (n)
Combined oral contraceptives 23
NSAIDs 20





Allergy and asthma medication 11
Have undergone abdominal surgery (Yes/No) 98/11
Type of abdominal surgery (n)





Removal of ovaries and/or oviducts 6
NSAID = non-steroidal anti-inflammatory drugs; SSRIs = selective serotonin
re-uptake inhibitors; PPIs = proton pump inhibitors; GnRH = gonadotropin
releasing hormone. The six most common currently used medications and
abdominal surgery are reported. Patients could have undergone more than
one examination, used more than one medication, and had more than one
type of abdominal surgery conducted. Values are given as number
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patients did not experience diarrhea. Thus, hormonal
treatment may have its main effect on endometriosis
and endometriosis-related symptoms, and less effect on
overall gastrointestinal symptoms.
To the best of our knowledge, this is the first study
that has investigated gastrointestinal symptoms among
patients with endometriosis using a continuous scale,
the VAS-IBS. Also, to the best of our knowledge, no
study has investigated the symptoms in respect to use of
opioids and GnRH analogs.
The findings of the present study partially support the
findings of previous studies in regard to bloating, ab-
dominal pain, and constipation among endometriosis
patients [3, 5]. However, in other studies, diarrhea, nausea,
and vomiting were reported to be common [3, 4]; however,
these symptoms were not more frequent among patients







Age (years) 36.78 ± 7.39 40.20 ± 8.75 0.036
Abdominal pain
Z-score −0.68 (−2.12–0.64) 0.30 (−0.43–0.70) 0.001
Absolute score 65.00 (30.00–100.00) 93.00 (73.00–98.00)
Missing value 2 8
Diarrhea
Z-score 0.25 (−1.18–0.69) 0.44 (−0.02–0.65) 0.617
Absolute score 87.00 (45.00–100.00) 95.00 (80.00–98.00)
Missing value 2 10
Constipation
Z-score −0.29 (−2.11–0.57) 0.43 (0.03–0.58) 0.009
Absolute score 80.00 (30.00–100.00) 95.00 (83.00–98.00)
Missing value 2 8
Bloating and flatulence
Z-score −0.94 (−1.8–0.46) 0.41 (−1.08–0.85) 0.000
Absolute score 45.00 (20.00–85.00) 81.50 (41.75–96.00)
Missing value 2 7
Nausea and vomiting
Z-score 0.33 (−0.95–0.50) 0.37 (0.11–0.48) 0.284
Absolute score 95.00 (65.00–100.00) 98.00 (92.00–99.00)
Missing value 2 10
Psychological
well-being
Z-score −0.52 (−2.54–0.91) 0.19 (−0.57–0.86) 0.005
Absolute score 75.00 (40.00–95.00) 85.00 (74.00–96.00)
Missing value 2 4
Influence on daily life
Z-score −0.42 (−1.83–0.57) 0.35 (−0.27–0.67) 0.001
Absolute score 70.00 (30.00–100.00) 96.00 (75.00–98.00)
Missing value 2 7
Defecation urgency
(Yes/No/Unknown) 37/66/6 11/52/2 0.010
Sensation of incomplete
evacuation
(Yes/No/Unknown) 53/50/6 17/46/2 0.050
Z-score = standard score. The z-scores were used for calculations with the Mann–Whitney U-test. Fisher’s exact test was used to calculate dichotomous variables.
P ≤ 0.05 was considered statistically significant. Values are given as mean ± standard deviation, median [interquartile range (IQR)], and number
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than controls in the current study. Previous studies have
reported exacerbation of symptoms during menstru-
ation [4, 6, 7]. This phenomenon does not differentiate be-
tween endometriosis and IBS, since not only abdominal
pain due to endometriosis, but also gastrointestinal symp-
toms due to functional bowel diseases have been shown to
increase during menstruation [19]. Symptoms were not
found to be more severe during menstruation in this study,
which can depend on few menstruating (n = 3) vs. non-
menstruating (n = 21) patients in the group of non-
hormonal treatment, since some patients experienced men-
struation as a trigger factor for gastrointestinal symptoms.
Symptoms including diarrhea, constipation, and colic rec-
tal pain have been reported to be more common among
patients with endometriosis lesions within or close to the
bowel than among patients with distant lesions [7, 9]. How-
ever, other studies have not found this association [3]. In
the current study, nausea and vomiting were associated
with bowel-related lesions, but no other symptom associ-
ation was detected. These findings, and the fact that hor-
monal endometriosis treatment did not influence
gastrointestinal symptoms over time, indicate an exist-
ing comorbidity between endometriosis and IBS.
One explanation for this possible comorbidity is an
immunological link, involving increased mast cell activa-
tion. In IBS, colonic mast cell activation and mediator
release close to mucosal innervation have been reported
[20], and in deep infiltrating endometriosis, the presence
of an increased number of activated mast cells close to
nerves have been described [21]. Issa et al. [22] suggested
that the visceral hypersensitivity found in both patients with
IBS and endometriosis could amplify gastrointestinal symp-
toms in patients with endometriosis. A hormonal link is
also plausible; GnRH-containing neurons [11] and recep-
tors for LH [23] have been shown to be present in the
human gastrointestinal tract as well as in the pelvic organs
[24, 25]. IBS is predominantly diagnosed in women, with a
female to male ratio ranging from 2:1 to 4:1, depending on
the diagnostic procedure [26]. Female sex hormones have
been suggested to be involved in IBS-associated pain, since
fluctuation in IBS symptoms has been reported with ex-
acerbation of abdominal pain during menstruation [19].
However, the mechanisms underlying these findings are un-
clear [26]. Exacerbation of gastrointestinal symptoms in
endometriosis patients during menstruation has also been
reported [4, 6, 7]. Another explanation for the symptoms
could be a yet undefined gastrointestinal disease or undis-
covered endometriosis in the intestinal wall.
Use of opioids is known to cause gastrointestinal
symptoms such as constipation, nausea, and abdominal
pain, in severe cases referred to as narcotic bowel syn-
drome [27]. Almost 20 % of the patients had been pre-
scribed opioids because of abdominal pain, and patients
with current opioid use had more severe symptoms on
Table 6 Gastrointestinal complaints among patients with endometriosis in relation to opioid use
Patients with current
opioid use n = 13
Patients with no
current opioid
use n = 94
P value
Abdominal pain
Absolute score 30.00 (10.00–57.50) 70.00 (45.00–100.00) 0.002
Diarrhea
Absolute score 75.00 (19.00–93.50) 90.00 (60.00–100.00) 0.046
Constipation
Absolute score 25.00 (10.00–48.00) 80.00 (45.00–100.00) 0.002
Bloating and flatulence
Absolute score 25.00 (15.50–40.00) 50.00 (20.00–90.00) 0.012
Nausea and vomiting
Absolute score 50.00 (20.00–65.00) 100.00 (75.00–100.00) 0.000
Psychological well-being
Absolute score 30.00 (5.00–57.50) 75.00 (50.00–100.00) 0.000
Influence on daily life







Calculations were made using the Mann Whitney U-test. Fisher’s exact test was used to calculate dichotomous variables. P ≤ 0.05 was considered statistically
significant. Values are given as median [interquartile range (IQR)] and number
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almost all parameters measured by the VAS-IBS than pa-
tients not using opioids. One explanation to these find-
ings is that the patients with severe symptoms were
prescribed opioids, but another explanation is that opi-
oids could cause or aggravate symptoms. A conclusion
to be drawn is that many endometriosis patients may
not benefit from opioid treatment. Perhaps, opioids have
no or weak positive impact on gastrointestinal symp-
toms; they possibly may even exacerbate them. Thus, all
initiating of opioid treatment in this patient group
must be carefully evaluated before continued. When
excluding current opioid-users, the endometriosis pa-
tients still had more severe symptoms than controls,
even though the P values were slightly higher than 0.05
in some parameters.
GnRH has been shown to be present in the ENS [11]
and has been linked to gastrointestinal function [12, 13],
but its role in gut physiology and pathophysiology has
not been completely elucidated. Hammar et al. [13] re-
ported increased symptoms of constipation, as well as
nausea and vomiting among women after treatment with
GnRH analogs, with exacerbation of abdominal pain
showing a tendency towards significance. At 5-year
follow-up, the patients had more abdominal pain than they
experienced prior to GnRH treatment [13], and some pa-
tients have developed severe dysmotility secondary to re-
peated or prolonged GnRH treatment [11, 14, 15]. In the
present study, patients treated with GnRH analogs had
more abdominal pain than the other patients. This could
have several explanations; one is that patients with more
severe symptoms received GnRH treatment, but another
plausible explanation is that the symptoms are due to side
effects evoked by GnRH on the ENS. Further research on
GnRH and its role in gastrointestinal function and dysfunc-
tion is needed.
The current study has several limitations. Approxi-
mately half of the patients identified as fulfilling inclusion
criteria declined to participate. One can hypothesize that
the patients who agreed to participate experienced more
severe symptoms, making them more prone to report
them. Another weakness is that the patient group and
control group were not matched regarding age. To
minimize the impact of this factor, z-scores were calcu-
lated and analyzed. However, age only correlated with
symptoms in patients and not in controls, and the patients
who declined to participate were slightly younger, which
correlated with more severe symptoms. The patients re-
ported pharmacological treatment of endometriosis and
gastrointestinal symptoms, and as the majority of patients
most likely had no medical education, one can assume that
they less accurately reported their symptoms. To minimize
inaccuracy, the pharmacological treatment was discussed at
the interview. When asked to measure abdominal pain on
the VAS-IBS, it is not clear whether patients responded
regarding pain related to endometriosis or gastrointestinal
symptoms. However, almost half of the patients reported
having the ability to differentiate pain from endometriosis
from that of the gastrointestinal tract. The patients appear
to be a selected group with high education and a healthy
lifestyle; they reported low consumption of alcohol and
tobacco. However, these habits could also be due to the fact
that alcohol and smoking exacerbate their symptoms.
This study has several clinical impacts. Endometri-
osis is a disease with a considerable diagnostic delay
[28], and an extended knowledge of symptoms associ-
ated with the disease could potentially contribute to
reducing this delay. It is also of importance to acknow-
ledge these symptoms in order to provide adequate
pharmacological treatment, especially since hormonal
treatment of endometriosis appeared to have no effect
on gastrointestinal symptoms. The findings also indicate
the importance of conservativeness in prescribing opioids
to this group of patients, especially if the indication is
gastrointestinal symptoms, because opioids appear to have
no or weak effect on these symptoms. Physicians must
carefully evaluate the effect of opioids and should withdraw
opioid treatment when the effect is uncertain.
Conclusions
A large proportion of patients with endometriosis suffer
from gastrointestinal symptoms. Compared to controls,
patients with endometriosis suffer from more severe ab-
dominal pain, constipation, bloating and flatulence, im-
paired psychological well-being, influence of symptoms
on daily life, defecation urgency, and sensation of incom-
plete evacuation. The location of the endometriosis lesions
is not associated with symptoms, except increased nausea
and vomiting among patients with lesions within or close
to the bowel. Patients treated with opioids have more
severe symptoms than patients not treated with opioids,
and current or previous treatment with GnRH analogs is
associated with increased abdominal pain. Initiating a new
hormonal treatment of endometriosis has no impact on
gastrointestinal symptoms over time.
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